JnJ to resume US VARIPULSE cases

The investigation into potential device-, procedure-, and patient-related factors concluded that VARIPULSE devices operate as intended and there is no difference in the performance of the available VARIPULSE system configurations globally. The investigation found the risk of neurovascular events may increase if a high number of ablations, the stacking of ablations, and/or ablations outside of the pulmonary veins are delivered.

VARIPULSE is an important treatment option for patients with atrial fibrillation and remains available in all markets where commercially launched.

"Johnson & Johnson will update the Instructions for Use (IFU) globally for the VARIPULSE Catheter to include enhanced guidance. The Company is communicating with healthcare professionals using VARIPULSE to recommend they review and adhere to the updated IFU and share information with patients. We will continue to educate healthcare professionals with guidance around recommended practices aligned to our clinical studies," JnJ stated in a recent release.

Globally, the VARIPULSE roll out has been successful, with over 3,000 commercial cases completed.

Read also: JnJ initiates submission of New Drug Application with USFDA for TAR-200 for BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation. Johnson & Johnson MedTech is addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation.

Read also: Johnson & Johnson MedTech launches CEREGLIDE 92 Catheter System for Acute ischemic stroke